Jump to content

Publication: Comparison of the Complications of Platinum-Based Adjuvant Chemotherapy With and Without Ginger in a Pilot Study on Ovarian Cancer Patients: Difference between revisions

From CAMIH
Created page with "{{Publication |Title=Comparison of the Complications of Platinum-Based Adjuvant Chemotherapy With and Without Ginger in a Pilot Study on Ovarian Cancer Patients |Topic=Ginger (also contains zerumbone) |Author=Shokri, F; Mostafa Gharebaghi, P; Esfahani, A; Sayyah-Melli, M; Jafari Shobeiri, M; Ouladsahebmadarek, E; Ghojazadeh, M |Year=2017 |Journal=International Journal of Woman's Health and Reproduction Sciences |DOI=https://doi.org/10.15296/ijwhr.2017.55 |Authors Abstrac..."
 
No edit summary
 
Line 1: Line 1:
{{Publication
{{Publication
|Title=Comparison of the Complications of Platinum-Based Adjuvant Chemotherapy With and Without Ginger in a Pilot Study on Ovarian Cancer Patients
|Title=Comparison of the Complications of Platinum-Based Adjuvant Chemotherapy With and Without Ginger in a Pilot Study on Ovarian Cancer Patients
|Topic=Ginger (also contains zerumbone)
|Topic=Ginger
|Author=Shokri, F; Mostafa Gharebaghi, P; Esfahani, A; Sayyah-Melli, M; Jafari Shobeiri, M; Ouladsahebmadarek, E; Ghojazadeh, M
|Author=Shokri, F; Mostafa Gharebaghi, P; Esfahani, A; Sayyah-Melli, M; Jafari Shobeiri, M; Ouladsahebmadarek, E; Ghojazadeh, M
|Year=2017
|Year=2017

Latest revision as of 14:11, 4 September 2024


Reference
Title Comparison of the Complications of Platinum-Based Adjuvant Chemotherapy With and Without Ginger in a Pilot Study on Ovarian Cancer Patients
Topic Ginger
Author Shokri, F, Mostafa Gharebaghi, P, Esfahani, A, Sayyah-Melli, M, Jafari Shobeiri, M, Ouladsahebmadarek, E, Ghojazadeh, M
Year 2017
Journal International Journal of Woman's Health and Reproduction Sciences
DOI https://doi.org/10.15296/ijwhr.2017.55

Author's Abstract The abstract and the information and conclusions contained therein were written by the authors of the publication.

Objectives: The principal treatment of ovarian cancer is surgery with or without chemotherapy. The chemotherapy, however, might be ineffective and long with serious side-effects. To obviate these shortcomings, more efficient and safer medications are required, among which ginger has recently gained popularity because of its anti-cancer properties. This study aims to compare outcomes and side-effects of adjuvant chemotherapy with and without ginger in ovarian cancer patients.

Materials and Methods: A total of 49 patients (20 patients in case group and 29 patients in control group) with stage I to III, histopathologically proved ovarian cancer underwent cytoreductive surgery followed by platinum-based adjuvant chemotherapy with and without investigator-prepared oral ginger capsules (2 g per day for 6 cycles). Potential side-effects, poor 12-month outcome (serum CA125 levels >35U, radiologic evidence of metastasis and recurrence, or death), and 12-month disease-free survival were documented and compared between the 2 groups. Results: Poor outcome including serum CA125>35, metastasis, recurrence or death was documented more common in control group (69% versus 40%). metastasis frequency confirmed by computerized tomography (CT) scan 6 month after treatment was significantly lower in case group (P = 0.04). There was no significant difference regarding mortality and disease free survival during one year follow-up after treatment between 2 groups (P = 0.55). Chemotherapy complications such as nausea, vomiting, weight loss, and peripheral neuropathy were detected in case group less than control group but the difference was not significant. Conclusion: Oral administration of ginger is along with a significantly better 12-month outcome in patients on chemotherapy because of ovarian cancer, and accordingly, considering its safety, its administration is recommended.



This publication is referenced in the following studies:

  1. Shokri et al. (2017): Comparison of the Complications of Platinum-Based Adjuvant Chemotherapy With and Without Ginger in a Pilot Study on Ovarian Cancer Patients